1
|
Kuribayashi M, Isono T, Satake Y, Yokochi Y, Kawamura T, Kishi R, Koreyasu R, Sakyo K, Watanabe T, Ueda T, Nozawa M, Tachibana M, Tsukamoto K, Kamimura K, Wada H. Sebaceous Carcinoma of the Breast in a Japanese Male with a BRCA2 Pathogenic Variant: Report of an Exceedingly Rare Case and Review of the Literature. Surg Case Rep 2025; 11:24-00543. [PMID: 39980666 PMCID: PMC11842163 DOI: 10.70352/scrj.cr.24-00543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2024] [Accepted: 11/14/2024] [Indexed: 02/22/2025] Open
Abstract
INTRODUCTION Sebaceous carcinoma (SC) is a malignant neoplasm differentiated from the mature sebocyte and occurs mainly in the periorbital area. However, SC of the breast is extremely rare. We report a case of sebaceous breast carcinoma in a Japanese man with a BRCA2 pathogenic variant. CASE PRESENTATION A 77-year-old Japanese man had been aware of a mass in his right breast for about a year and had visited his previous physician for a follow-up. Over the next year, the mass grew, and the last doctor he visited referred him to our hospital for further examination and treatment. Physical examination revealed a palpable 3-cm-large mass of the right breast. There was no skin invasion, and core needle biopsy revealed invasive ductal carcinoma cT2N1M0 cStage IIB, estrogen receptor (+)/progesterone receptor (+)/HER2/neu (-)/Ki-67 labeling index: 27.8%. His daughter had a history of breast cancer, and he had a BRCA2 pathogenic variant. The patient underwent a total right mastectomy and axillary lymph node dissection. Pathological diagnosis was primary SC of the breast, pT2N0M0, pStage IIA. His postoperative clinical course was good. Postoperatively, the patient received endocrine therapy and S-1 for 1 year and is currently receiving endocrine therapy alone. One year and 5 months have passed since the operation, with no recurrence or metastasis noted. CONCLUSIONS The prognosis of SC of the breast has not been elucidated. As cases of SC with a BRCA2 pathogenic variant are exceedingly rare, it will be necessary to continue accumulating cases in the future to understand this disease further. This research is essential to elucidating SC.
Collapse
Affiliation(s)
- Mamika Kuribayashi
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Tadahiro Isono
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Yuichi Satake
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Yuta Yokochi
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Tomoki Kawamura
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Ryosuke Kishi
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Ryohei Koreyasu
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Konomi Sakyo
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Takahiro Watanabe
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Takeshi Ueda
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Masashi Nozawa
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Mitsuhiro Tachibana
- Department of Diagnostic Pathology, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Kei Tsukamoto
- Department of Diagnostic Radiology, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Kazuyasu Kamimura
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| | - Hidetoshi Wada
- Department of Surgery, Shimada General Medical Center, Shimada, Shizuoka, Japan
| |
Collapse
|
2
|
Cohen LN, Flanagan C, Kong AL, Cortina CS. A systematic review of sebaceous carcinoma of the breast from 2000-2023: A rare entity with high recurrence rates. SURGICAL ONCOLOGY INSIGHT 2024; 1:100074. [PMID: 39130075 PMCID: PMC11310847 DOI: 10.1016/j.soi.2024.100074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/13/2024]
Affiliation(s)
- Lauren N. Cohen
- Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, United States
| | - Colleen Flanagan
- Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, United States
| | - Amanda L. Kong
- Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, United States
- Medical College of Wisconsin Cancer Center, Milwaukee, WI, United States
| | - Chandler S. Cortina
- Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, United States
- Medical College of Wisconsin Cancer Center, Milwaukee, WI, United States
| |
Collapse
|
3
|
Cao L, Parvizi J, Zhang X, Liu X, Zijlstra WP, Tarabichi S. Editorial: Management of PJI/SSI after joint arthroplasty. ARTHROPLASTY 2024; 6:31. [PMID: 38840191 PMCID: PMC11155056 DOI: 10.1186/s42836-024-00256-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Accepted: 04/30/2024] [Indexed: 06/07/2024] Open
Abstract
The management of periprosthetic joint infection (PJI) and surgical site infection (SSI) after joint arthroplasty poses a major challenge in orthopedic surgery. This Editorial provides an overview of the studies published in the special issue "Management of PJI/SSI after Joint Arthroplasty", summarizing the key findings from these studies, which cover a wide range of topics, including stringent preventive strategies, comprehensive diagnostic methods, and personalized treatment modalities. The authors concluded the editorial with their perspectives regarding the status quo of research in this field and future directions for research, such as the development of novel antibiotics, biofilm research, patient-specific risk factors, and the integration of technological advancements (such as machine learning and artificial intelligence) into clinical practice. The authors emphasized the need for continued research, interdisciplinary collaboration, and the application of innovative technologies to enhance patient outcomes and mitigate the burden of these infections on healthcare systems.
Collapse
Affiliation(s)
- Li Cao
- Department of Orthopedics, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, China.
| | - Javad Parvizi
- International Joint Center, Acibadem University Hospital, Istanbul, 34746, Turkey
| | - Xiaogang Zhang
- Department of Orthopedics, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, China
| | - Xianzhe Liu
- Department of Orthopedic Surgery, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
| | - Wierd P Zijlstra
- Department of Orthopedic Surgery, Medical Center Leeuwarden, 8934 AD, Leeuwarden, the Netherlands
| | - Saad Tarabichi
- Rothman Orthopedic Institute at Thomas Jefferson University Hospital, Philadelphia, PA, 19107, USA
| |
Collapse
|
4
|
Abstract
PURPOSE OF REVIEW Breast cancer is a collection of diseases including the more common invasive ductal and lobular carcinomas and rarer subtypes of breast cancer. This review summarizes the features of rare breast cancers. RECENT FINDINGS Each of the rare tumors has defined pathological and clinical features that impact treatment recommendations. In this review, we summarize these for each rare type of breast cancer and where available we include molecular features of each tumor. Rare subtypes of breast cancer each have unique features. In many cases, data is limited for the optimal treatment approaches.
Collapse
Affiliation(s)
- Sarah Jenkins
- Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA
- Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA
| | - Megan E Kachur
- Pathology Department, Walter Reed National Military Medical Center, Bethesda, MD, 20889, USA
| | - Kamil Rechache
- Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA
| | - Justin M Wells
- Pathology Department, Walter Reed National Military Medical Center, Bethesda, MD, 20889, USA.
| | - Stanley Lipkowitz
- Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
| |
Collapse
|
5
|
De Vincentiis L, Mariani MP, Cesinaro AM, Dalena AM, Ferrara G. Sebaceous Carcinoma of the Breast: Fact or Fiction? A Case Report and a Review of the Literature. Int J Surg Pathol 2020; 29:211-215. [PMID: 32608286 DOI: 10.1177/1066896920937784] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction. Previously considered an exceedingly rare entity, sebaceous carcinoma of the breast is now regarded in the World Health Organization 2019 classification as a "special histopathological pattern" of invasive breast carcinoma of no special type. Case Description. In this article, we report the case of a fine needle aspiration cytology and the histopathological features of a breast carcinoma with clear-cut morphological features suggesting sebaceous differentiation, but showing no positive staining with the anti-adipophilin antibody. Conclusions. A morphologically clear-cut sebaceous differentiation is not invariably associated with adipophilin positivity; moreover, in breast carcinoma, adipophilin positivity does not automatically imply sebaceous differentiation. At present, immunomorphological evidence for the recognition of sebaceous carcinoma as a "special type" breast carcinoma subtype is too weak.
Collapse
|